Loading
Co-discovered that BRCA-deficient cancers die when PARP is blocked, the idea behind an entire drug class.
Alan Ashworth is President of the UCSF Helen Diller Family Comprehensive Cancer Center and a molecular biologist specialising in DNA repair, synthetic lethality, BRCA and PARP inhibitors. He co-identified BRCA2 and, with colleagues at the Institute of Cancer Research, showed that BRCA-deficient cells die when PARP is blocked, the synthetic lethality behind olaparib and the PARP inhibitor class. His papers include the Nature report on targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy and a review of synthetic lethal therapies beyond PARP inhibitors, with relevance to ovarian cancer and triple-negative breast cancer. He now leads UCSF's cancer centre.
| Title | Journal | Year |
|---|---|---|
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Nature | 2005 |
| Synthetic lethal therapies for cancer: what's next after PARP inhibitors? | Nature Reviews Clinical Oncology | 2018 |
Shares Synthetic lethality approaches, PARP, PARP inhibitors, Olaparib.
Shares Synthetic lethality approaches, PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD).
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares Synthetic lethality approaches, PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD).
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).